NCT01494688View on ClinicalTrials.gov

A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

December 20, 2011

Primary Completion Date

February 7, 2018

Study Completion Date

February 7, 2018

Conditions
Advanced Solid Tumors
Interventions
DRUG

Paclitaxel

Paclitaxel, at a dose of 80 mg/m\^2 will be administered QW for up to 12 weeks.

DRUG

RO5509554

RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

19104

Univ of Pennsylvania Med Ctr, Philadelphia

31059

Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse

33076

Institut Bergonie; Oncologie, Bordeaux

44805

Ico Rene Gauducheau; Oncologie, Saint-Herblain

69373

Centre Leon Berard; Departement Oncologie Medicale, Lyon

75231

Institut Curie; Oncologie Medicale, Paris

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01494688 - A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter